COVID-19 and Pulmonary Hypertension: An Interesting Dynamic.

Publication date: Feb 24, 2024

The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. Several factors are suggested to contribute to an increased risk of developing PH after infection with SARS-CoV-2. This includes cytokine storm, acute respiratory distress syndrome, and fibrotic changes seen in post-COVID-19 lung disease. Additionally, it has been proposed that certain medications used to treat PH may be applied to patients suffering from the cardiopulmonary complications of COVID-19. This review will focus on the interplay between COVID-19 and PH, with a special focus on the risk of developing PH after SARS-CoV-2 infection and the outcomes of patients with preexisting PH who are diagnosed with COVID-19. The potential benefits of utilizing off-label PH medications for COVID-19 patients will also be discussed.

Concepts Keywords
Cardiol Cardiopulmonary
Hypertension Cov
Investigators Covid
Storm Developing
Dynamic
Focus
Hypertension
Infection
Interesting
Interplay
Medications
Ph
Pulmonary
Risk
Sars

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Pulmonary Hypertension
disease MESH infection
disease MESH cytokine storm
disease MESH acute respiratory distress syndrome
disease MESH lung disease
disease MESH complications
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)